Get the Stockscreener App
19.55
0.20%
-0.04
Pre-market:
19.75
0.20
+1.02%
Dyne Therapeutics Inc stock is traded at $19.55, with a volume of 3.15M.
It is down -0.20% in the last 24 hours and up +4.04% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$19.59
Open:
$19.33
24h Volume:
3.15M
Relative Volume:
1.06
Market Cap:
$3.16B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-5.0648
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
+6.02%
1M Performance:
+4.04%
6M Performance:
+41.46%
1Y Performance:
-25.10%
1-Day Range:
$19.06
$19.84
1-Week Range:
$19.06
$20.80
52-Week Range:
$6.36
$26.69
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.55 | 3.17B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Oppenheimer upgrades Dyne Therapeutics to outperform, raises target to $40 - MSN
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Evercore ISI Maintains and Lowers Price Target for Dyne Therapeu - GuruFocus
Dyne Therapeutics, Inc. (NASDAQ:DYN) Nasdaq Index Genetic Therapy Pathways - Kalkine Media
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Frazier Life Sciences Management L.P. Has $14.34 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Bets Big On Breakthrough Muscle Disease Treatments - Finimize
TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
Braidwell LP Has $31.16 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics offers to sell $300M in common stock - MSN
WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock - WilmerHale
Why Dyne Therapeutics stock was a big winner on Wednesday - MSN
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) - The Globe and Mail
HighVista Strategies LLC Sells 52,096 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne’s Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year - MSN
Armistice Capital LLC Has $24.37 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Stifel Maintains Dyne Therapeutics (DYN) Buy Recommendation - Nasdaq
Dyne Therapeutics raises $402.5 million in upsized public offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics raises $402.5 million in upsized public offering - Investing.com
Dyne Therapeutics prices $350 stock offering - MSN
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $39.00 at Stifel Nicolaus - MarketBeat
Dyne, citing positive trial data, to ask FDA to approve DMD therapy - Muscular Dystrophy News
Dyne Therapeutics 18.98M-share secondary priced at $18.44 - MSN
Stifel Raises Price Target for Dyne Therapeutics (DYN) to $39.00 - GuruFocus
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial - Insider Monkey
Dyne Therapeutics price target raised to $23 from $21 at Bernstein - MSN
Stifel maintains Dyne Therapeutics (DYN) buy recommendation - MSN
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% U - GuruFocus
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday - Finviz
Oppenheimer Upgrades Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics Announces Upsized Public Offering - TipRanks
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% Upside - GuruFocus
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Dyne Therapeutics: Why The $350M Public Offering Was Critical (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics Surges Amid Positive Trial Results and Financial Adjustments - timothysykes.com
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
Oppenheimer Upgrades Dyne Therapeutics to Outperform From Perform, Adjusts PT to $40 From $11 - marketscreener.com
Dyne Therapeutics (DYN) Sees Upgrade and Potential Stock Upside - GuruFocus
HC Wainwright Has Positive Outlook for DYN FY2027 Earnings - MarketBeat
Dyne Therapeutics Prices $350 Million Public Offering - marketscreener.com
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - Sahm
Why Dyne Therapeutics Stock Tanked on Tuesday - Finviz
Dyne Therapeutics prices upsized public offering at $18.44 per share By Investing.com - Investing.com Nigeria
Dyne Therapeutics Prices Upsized Public Offering Of 18.98 Mln Shares - Nasdaq
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):